Risk for Zoster Up Before Dx, During Tx of Hematologic Cancer
The risk for herpes zoster (zoster) is elevated during the two years preceding diagnosis and during treatment of hematological cancer.
Hematologic Disorders
Nplate Indication Expanded to Include Pediatric Patients With ITP
The expanded approval was supported by data from 2 double-blind, placebo-controlled trials in patients aged ≥1 year with ITP for at least 6 months.
Reversal of Warfarin-Associated Bleeding With 4F-PCC Examined in Obese Patients
To investigate an appropriate dosing strategy for 4F-PCC (Kcentra; CSL Behring) in obese patients, the authors conducted a retrospective analysis comparing the reversal of warfarin using adjusted (N=28) vs actual body weight (N=50).
Smartphone App Uses Fingernail Bed Images to Detect Anemia
App uses color and metadata from fingernails to detect hemoglobin levels in the blood
FDA Approves Updated Labeling for Hemophilia A Treatment Novoeight
The indication has been changed from “control and prevention of bleeding episodes” to “on-demand treatment and control of bleeding episodes” in adults and children with hemophilia A.
Amicar Tablet Generic Gets FDA Approval
Aminocaprioc Acid Tablets are useful in enhancing hemostasis when fibrolysis contributes to bleeding.
FDA: Serious Side Effect of AML Drug Not Being Recognized
From May 1 2018 to July 31 2018, 5 cases of death associated with DS in patients taking Idhifa have been reported; in 2 of these cases, DS was listed as the only cause of death.
Xospata Approved for Relapsed/Refractory AML With FLT3 Mutation
Xospata was evaluated in the Phase 3 open-label, multicenter, randomized ADMIRAL trial (N=138) which included patients with relapsed or refractory AML with a FLT3 ITD, D835, or I836 mutation.
First Rituximab Biosimilar Truxima Gets FDA Approval
The FDA approval was supported by clinical data describing structural and functional characterization, preclinical data, human pharmacokinetic data, clinical immunogenicity data, and other data which showed no clinically meaningful differences between Truxima and Rituxan.
Lanadelumab Examined for Attack Rate in Hereditary Angioedema
During the treatment period, the mean number of attacks per month was 1.97 for placebo and 0.48, 0.53, and 0.26 for the lanadelumab groups, respectively. The mean differences in the attack rate per month compared with placebo were −1.49, −1.44, and −1.71, respectively.
